The question was narrow and the answer was careful, and both of them tell you most of what happened in the Senate hearing room on Thursday.
Senator Bill Cassidy, a physician from Louisiana who chairs the committee that will decide whether Dr. Heidi Overton leads the Food and Drug Administration, asked her whether the measles, mumps and rubella vaccine is safe and effective. She said it is, and that every vaccine on the American market is. Then he asked her to do something else: to reject the president's description of that same vaccine as potentially lethal, spoken while she stood behind him in the Oval Office.
She affirmed the vaccine. She did not correct the president.
The question Cassidy asked
Overton, a preventive medicine physician who has been serving as a White House domestic policy adviser, was nominated in August to run an agency that has been without a confirmed leader since May. Her hearing before the Senate Health, Education, Labor and Pensions Committee produced a set of exchanges that were less about her credentials than about where her judgment would stop and the White House's would begin.
AP reported that she told the panel that every vaccine on the market has been determined to be safe and effective, and she described the MMR shot as the best tool available in the response to the country's worst measles outbreak in decades.
The follow-up is where it got difficult. Asked later to say plainly that the president was wrong about the vaccine's safety, she did not, according to the same account. The committee chairman returned to it, in the phrasing of someone who had heard a commitment before: he told her the committee needed to know whether she would stand up for sound science and protect children's health.
Cassidy's frustration has a specific history behind it. When he voted to confirm Robert F. Kennedy Jr. as health secretary, he said he had been given guarantees about vaccine policy. On Thursday he said those guarantees had not held, and that Kennedy had told him the president's instructions took precedence over the promises he had made to the committee. That account matters for how the panel reads Overton's answers, because it establishes what a promise made in that room is worth once the nominee holds the job.
The White House moved on vaccine policy without waiting for a confirmed commissioner. An executive order signed in August directs states to revise the recommended childhood immunization schedule, splitting the MMR vaccine into separate shots. Cassidy, who is a physician, said the order rested on no scientific evidence and would raise costs for families. There is no credible scientific evidence connecting the vaccine to autism, a claim the president has repeated.
An agency that has been shedding its people
The FDA Overton would inherit is thinner than the one her predecessors ran. It has lost more than 4,500 employees over the past year through layoffs, buyouts, retirements and resignations, roughly a fifth of its workforce, and its previous commissioner, Dr. Marty Makary, resigned in May. Kyle Diamantas has led it on an acting basis since then.
That matters more for a regulator than it would for most agencies, because the FDA's authority rests on the workforce that does the reviewing. Drug applications, device clearances, food safety inspections and vaccine determinations are made by career scientists operating inside procedures that are designed to be repeatable regardless of who runs the building. When a nominee is asked whether she would follow the science, part of the answer is structural rather than personal: the science at an agency of sixteen thousand people is a process, and processes are staffed. A commissioner who wanted to bend an outcome has to work through reviewers, committees and published standards, which is slow and visible. A commissioner who wanted to hollow out that capacity would find it much easier, because vacancies do not make headlines the way decisions do. The number to watch over the next year is not the commissioner's rhetoric but the agency's headcount.
Overton's resume carries a different kind of qualification and a visible gap. She studied under Makary at Johns Hopkins, where she earned a doctoral degree in clinical research after her medical degree, and she has spent her recent career in the White House policy apparatus rather than running a large bureaucracy. In her financial disclosures she reported no investments in healthcare or food companies, a contrast with several recent nominees who had to unwind holdings before taking a position with authority over their former investments.
There is a countervailing signal in how the agency has been staffed around her. HHS has installed more conventional figures in the two drug review offices that handle most of the agency's decisions, and both were given the jobs permanently in early September after months of acting appointments, a move that analysts covering the sector treated as a stabilizing step.
Where she declined to answer
The exchanges that drew the most attention were about a drug rather than a vaccine. Mifepristone has been approved since 2000, and the FDA has repeatedly affirmed its safety while broadening how it can be obtained, including delivery by mail. Kennedy ordered a review of the drug's safety last year after pressure from groups seeking to restrict abortion access, and that review is still open.
Overton wrote, while at the America First Policy Institute, that mail delivery of the drug was dangerous to women. On Thursday she did not repeat that view and did not withdraw it. She told senators that the agency had found the drug met its standards for safety and effectiveness, and she said she would follow the law while declining to prejudge the outcome of the review now underway. Senator Patty Murray of Washington pressed her on whether she believed the drug is safe and effective herself, and Murray said afterward that the answer had not been given.
A related exchange went further. Overton declined twice to say whether an intrauterine device is a form of birth control rather than a method of abortion, saying she would want to be briefed on the agency's prior positions before answering. Murray called that response outrageous. For a committee weighing whether a nominee will follow settled science, a refusal to describe a device the way the agency describes it is not a small thing, because it is a question with a documented answer.
She did contradict the president on one point of medicine. She rejected his claim that Tylenol is linked to autism, which is not supported by the evidence, while declining to fault him for telling pregnant women to avoid the drug on the basis of it.
The vaping decision and the standard inside it
Senator Susan Collins of Maine raised a separate decision in front of the agency, the authorization of new flavored nicotine pouches and e-cigarettes. She described the authorizations as a terrible decision that could reverse progress on youth vaping, and she asked Overton to disavow them.
Overton did not. She said career FDA staff had recommended the products because many adults who quit smoking use flavors preferentially, and she indicated that the products had been found to meet the standard of being appropriate for the protection of public health.
The exchange is worth reading closely, because it is the clearest illustration of how agency decisions get defended. The question was whether the outcome was right. The answer was that the process produced it. Under prior administrations, including the president's first term, the agency had restricted sweet vaping flavors over their appeal to children, so the same standard has now yielded a different result. Overton's position was that she would rely on the staff who applied it. Whether that is deference to expertise or deference to whoever else sets the direction is the question the committee was trying to answer all afternoon.
What confirmation would and would not settle
Overton also told the panel she would work to speed early-stage drug research, pointing to the administrative push to keep clinical development in the United States as China's biotechnology sector advances. An analyst at RBC Capital Markets called the hearing a net positive for the sector, citing her emphasis on innovation and the expectation that valued agency practices, advisory committees among them, would continue.
To reach the job she needs a majority of the twenty-one member committee and then a majority of the full Senate, and the chairman did not say on Thursday whether he would support her or when a vote might be scheduled. Two Republicans on the panel, Collins and Lisa Murkowski of Alaska, have broken with their party on abortion access, and Overton's record on the subject gives them a reason to weigh their votes rather than fall in behind the nomination. Collins is running for reelection with abortion among the central issues of the race.
The structural limit is worth stating plainly, because hearings obscure it. A commissioner is a presidential appointee who reports through the health secretary, and the commitments a nominee gives at a confirmation hearing are not enforceable once the votes are counted. The committee's leverage exists only in the interval before it votes. That is why Cassidy's line of questioning sounded like a man taking a deposition rather than an interview: he was trying to lock in a record he can point to later.
What the FDA will do on vaccines and on the drug under review in the coming year will depend on the president's instructions, the career staff who stay, and the willingness of a commissioner to absorb a conflict rather than delegate it. Overton spent several hours showing the committee how she handles that kind of pressure. She affirmed what the evidence says when asked directly. She declined to say the president was wrong when asked to.
Primary sources
- The Associated Press, via NBC Chicago, for the hearing exchanges, Overton's statements on vaccine safety and the abortion pill, her earlier published criticism of mail delivery of mifepristone, the committee vote threshold, the agency's staffing losses and her financial disclosures.
- Reuters, via Hawaii Tribune-Herald, for Cassidy's account of the guarantees he received from the health secretary, the executive order on the childhood vaccine schedule, the Tylenol exchange and the measles outbreak context.
- BioPharma Dive, for the committee's composition, Overton's remarks on drug development and competition with China, the agency's recent leadership appointments and analyst reaction to the hearing.